Zydus Lifesciences Ltd - 532321 - Intimation Under Regulation 30
Intimation under regulation 3030-12-2022
30-12-2022
Zydus Lifesciences Ltd - 532321 - Consolidated Results Under Reg 44(3)
Consolidated results under Reg 44(3)30-12-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Triazolam Tablets30-12-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201527-12-2022
Zydus Lifesciences Ltd - 532321 - Closure of Trading Window
Intimation of Closure of Trading Window26-12-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201524-12-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement published in the Financial Express English and Gujarati Edition with regard to the Notice to the shareholders for claiming their shares which are proposed to be transferred to Investor Education and Protection Fund ('IEPF').22-12-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval and 180 days shared exclusivity from the USFDA for Selexipag Tablets22-12-2022